ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 121 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,478,615 | -78.4% | 223,261 | -69.6% | 0.00% | -75.0% |
| Q2 2023 | $20,694,208 | +489.9% | 733,577 | +259.7% | 0.00% | +300.0% |
| Q1 2023 | $3,507,871 | -55.4% | 203,946 | -47.8% | 0.00% | -50.0% |
| Q4 2022 | $7,862,294 | +7.3% | 390,382 | +15.4% | 0.00% | 0.0% |
| Q3 2022 | $7,329,000 | -34.4% | 338,332 | -14.9% | 0.00% | -33.3% |
| Q2 2022 | $11,171,000 | -8.7% | 397,570 | +49.9% | 0.00% | 0.0% |
| Q1 2022 | $12,238,000 | +3.0% | 265,246 | +87.6% | 0.00% | +50.0% |
| Q4 2021 | $11,883,000 | -22.6% | 141,369 | -38.6% | 0.00% | -33.3% |
| Q3 2021 | $15,350,000 | +242.3% | 230,341 | +173.3% | 0.00% | +200.0% |
| Q2 2021 | $4,484,000 | +99.5% | 84,289 | +62.7% | 0.00% | 0.0% |
| Q1 2021 | $2,248,000 | -80.7% | 51,809 | -76.9% | 0.00% | -66.7% |
| Q4 2020 | $11,633,000 | +1005.8% | 223,983 | +596.2% | 0.00% | – |
| Q3 2020 | $1,052,000 | +58.4% | 32,171 | +132.8% | 0.00% | – |
| Q2 2020 | $664,000 | – | 13,820 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |